Precision Medicine Group

Project Farma is a consulting firm that provides specialized services to healthcare companies within the pharmaceutical and medical device sectors. The firm focuses on biomanufacturing strategy and execution, assisting clients with capital projects, technology transfers, facility construction, and strategy development. Additionally, Project Farma offers expertise in validation processes and ensures compliance with regulatory standards. By addressing the complete supply chain, the firm aims to enhance operational efficiency and support the successful development and production of healthcare products.

ProMedDx is a leading contract research organization specializing in biobanking services. The company operates in the life sciences sector, providing essential human biologics and supporting clinical services. ProMedDx offers a range of solutions, including annotated biospecimens, patient recruitment, prospective specimen collection, biospecimen procurement, bioprocessing, biostorage, and clinical study monitoring. By facilitating global biospecimen management and direct-to-patient connections, ProMedDx supports the biobanking industry in its research and clinical endeavors, earning a reputation as a trusted partner in the field.

Stern Investor Relations, Inc. is an investor relations firm that focuses on serving biotechnology and healthcare companies. Founded in 1998 and headquartered in New York, the firm provides a range of services tailored to the unique needs of entrepreneurial organizations in these sectors. Stern Investor Relations offers expertise in investor and industry research, material assessment, opportunity analysis, strategy development, ESG advising, and executive education. This comprehensive approach enables clients to effectively navigate the complexities of going public and to maintain ongoing investor engagement. As of December 2018, Stern operates as a subsidiary of Precision Medicine Group, Inc., enhancing its capabilities in the dynamic healthcare landscape.

ApoCell, Inc. is a clinical research company based in Houston, Texas, specializing in molecular biomarker detection and analysis. Founded in 2004, it focuses on identifying and analyzing biomarkers in rare circulating cells, particularly in the fields of oncology, diabetes, and drug development. The company provides a comprehensive range of services including clinical trial support, biomarker consultation, customized assay development, and sample logistics. ApoCell's innovative technologies enable the isolation and analysis of circulating tumor cells (CTCs) and other rare cells from whole blood without the need for invasive biopsies, making diagnostics less invasive and more efficient. The company has participated in over 120 clinical trials for various cancers and has developed patented tools and platforms, such as ApoStream, for the enhanced detection of CTCs. Its facilities are CLIA-approved and compliant with FDA regulations, serving pharmaceutical and biotechnology clients, as well as academic institutions globally. ApoCell operates as a subsidiary of Precision for Medicine, Inc. and has a partnership with Cancer Genetics, Inc.

Epiontis, founded in 2003 and based in Berlin, Germany, specializes in immune response monitoring and epigenetic assay development. The company utilizes innovative molecular diagnostics technology to provide services that characterize immune status in patients, particularly those undergoing immune-modulating therapies for conditions such as autoimmune diseases and cancer. Epiontis offers a range of established assays for immune cell types, including regulatory T cells and tumor infiltrating lymphocytes, while also developing customized immunomonitoring assays tailored to specific research or clinical needs. Their aim is to support drug companies in immuno-oncology and autoimmune sectors by accelerating the development of effective therapies through precise immune cell monitoring and analysis.

Applied Immunology is a provider of contract research laboratory services to support the development of biological therapeutics.